Skip to main navigation
Cue Logo
Skip to Content
Cue Logo
  • Overview
  • News & Events
    • News Releases
    • Events and Presentations
  • Corporate Governance
    • Governance Overview
    • Committee Composition
  • Financials & Filings
    • SEC Filings
    • Quarterly Results
  • Stock Information
    • Stock Quote
    • Analyst Coverage
  • Resources
    • Investor FAQs
    • Email Alerts
    • Contact Investor Relations

News
Releases

Date Title
May 13, 2024
Cue Health Evaluating Warning Letter Received from Food and Drug Administration (FDA)
Apr 29, 2024
Cue Health to Announce First Quarter Financial Results
Mar 20, 2024
Cue Health Announces Strategic Actions to Position Company for Next Stage
Mar 13, 2024
Cue Health Reports Fourth Quarter 2023 Financial Results
Feb 28, 2024
Cue Health to Announce Fourth Quarter and Full Year 2023 Financial Results
Feb 16, 2024
Cue Health Announces Appointment of Rishi Reddy to Board of Directors
Jan 31, 2024
Cue Health to Participate at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Shareholder Tools

Print Page Print Page
Email Alerts Email Alerts
RSS RSS
Contact Contact

This website contains depictions of contemplated future products and future care offerings that are still under development by Cue Health and that have not received regulatory authorization, clearance or approval. Currently, Cue Health's products authorized for commercial sale in the United States are the Cue COVID-19 Test Kit and the Cue Mpox Molecular Test Kit, both authorized under Emergency Use Authorization from the U.S. Food & Drug Administration (the “FDA”) and the COVID-19 Molecular Test Kit (De Novo granted by the FDA).

  • © 2024 Cue Health Inc. All rights reserved. Cue and the Cue logo are registered trademarks of Cue Health Inc.